

Submit a Manuscript: http://www.f6publishing.com

World J Gastroenterol 2017 December 7; 23(45): 8073-8081

DOI: 10.3748/wjg.v23.i45.8073

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

SYSTEMATIC REVIEW

Double-balloon enteroscopy-assisted dilatation avoids surgery for small bowel strictures: A systematic review

Judith E Baars, Ruben Theyventhiran, Patrick Aepli, Payal Saxena, Arthur J Kaffes

Judith E Baars, Ruben Theyventhiran, Patrick Aepli, Payal Saxena, Arthur J Kaffes, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, Sydney NSW 2050, Australia

ORCID number: Judith E Baars (0000-0003-2634-0655); Ruben Theyventhiran (0000-0002-0085-6672); Patrick Aepli (0000-0001 -6114-9923); Payal Saxena (0000-0003-3097-6314); Arthur J Kaffes (0000-0003-1487-8159).

Author contributions: Baars JE performed the research and wrote the manuscript, Theyventhiran R and Aepli P collected and reviewed the data; Saxena P and Kaffes AJ managed the study; all authors read and approved the final version of the manuscript.

Conflict-of-interest statement: All the authors declare that they have no competing interests.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Arthur J Kaffes, MBBS, FRACP, Associate Professor, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Suite G10, RPA Medical Centre, 100 Carillon Ave, Camperdown, Sydney NSW 2050, Australia. arthur@kaffes.com Telephone: +61-295-162033 Fax: +61-295-160778

Received: July 20, 2017 Peer-review started: July 20, 2017 First decision: September 4, 2017 Revised: September 17, 2017 Accepted: October 17, 2017 Article in press: October 17, 2017 Published online: December 7, 2017

Abstract

AIM

To evaluate the therapeutic role of double-balloon enteroscopy (DBE) in small bowel strictures and to propose a standard approach to small bowel strictures.

METHODS

Systematic review of studies involving DBE in patients with small bowel strictures. Only studies limited to small bowel strictures were included and those with ileo-colonic strictures were excluded.

RESULTS

In total 13 studies were included, in which 310 patients were dilated. The average follow-up time was 31.8 mo per patient. The complication rate was 4.8% per patient and 2.6% per dilatation. Surgery was avoided in 80% of patients. After the first dilatation, 46% were treated with re-dilatation and only 17% required surgery.

CONCLUSION

DBE-assisted dilatation avoids surgery in 80% of patients with small bowel strictures and is safe and effective. We propose a standardized approach to small bowel strictures.

Key words: Double-ballloon enteroscopy; Dilatation; Small bowel stricture; Enteroscopy; Crohn's disease; Systematic review

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: At present there is a wealth of literature on the value of double-balloon enteroscopy (DBE) in the management of obscure gastrointestinal bleeding.



WJG | www.wjgnet.com

However, there is only few data regarding its role in small bowel strictures and these patients often face surgery. In our study we show that DBE-assisted endoscopic balloon dilation offers safe and effective treatment of small bowel strictures. Surgery can be avoided in 80% of cases. Moreover, we propose a flowchart representing a standard approach to small bowel strictures.

Baars JE, Theyventhiran R, Aepli P, Saxena P, Kaffes AJ. Doubleballoon enteroscopy-assisted dilatation avoids surgery for small bowel strictures: A systematic review. *World J Gastroenterol* 2017; 23(45): 8073-8081 Available from: URL: http://www. wjgnet.com/1007-9327/full/v23/i45/8073.htm DOI: http://dx.doi. org/10.3748/wjg.v23.i45.8073

INTRODUCTION

Small bowel strictures are associated with major comorbidity and adequate management is therefore required. The aetiology of small bowel strictures is varied and includes Crohn's disease (CD), postsurgical, ischemic, non-steroidal anti-inflammatory drugs (NSAIDs) induced, neoplastic and idiopathic^[1,2]. Endoscopic access into the small bowel is not widely available. Hence, surgery has been the mainstay for treatment for small bowel strictures. However, surgery is associated with serious complications including bowel obstruction, intra-abdominal infections, wound infections, anastomotic leakages and fistulas. In patients with CD, the complication rate can be as high as 20%^[3]. Besides the direct complications of surgery, there is also a > 70% chance of re-stricturing and it is known that multiple small intestinal resections can lead to short bowel syndrome and malnutrition^[4-6]. Endoscopic balloon dilation (EBD) has been extensively described for fibrostenosing CD as it is minimally invasive and preserves intestinal length^[7]. However, small bowel strictures are often more difficult to treat given their anatomical location.

In 2001 Yamamoto et al^[8] first described doubleballoon enteroscopy (DBE) as a new method to visualise the small bowel. Additionally, DBE provides the opportunity to perform therapeutics in the small bowel. Complications of DBE that have been described include bleeding, perforation and pancreatitis and however the rates are low ranging from 2%-18%^[9,10]. There have been many publications regarding the diagnostic and therapeutic roles of DBE. However, most of these publications have been limited to obscure gastrointestinal bleeding and there is limited data on its role in the management of small bowel strictures^[9,10]. Furthermore, previously published data are limited by small series and selection bias. Moreover, there is no clear data to recommend a safe and effective approach to endoscopic balloon dilatation (EBD) of small bowel strictures.

Our aim was to perform a systematic review of the published literature on DBE in small bowel strictures to evaluate the therapeutic role and safety of DBE in management of these strictures. Based on the reviewed data we aim to propose a standardized approach to EBD of small bowel strictures.

MATERIALS AND METHODS

A systematic search was performed in the Medline, PubMed and endbase databases including relevant references for English only articles using the following search terms: small bowel strictures, enteroscopy, balloon dilation/dilatation, double-balloon endoscopy. We only included small bowel strictures and excluded ileo-colonic anastomotic strictures. There were two papers from Hirai et al^[11] that included the same patient population, so we excluded the first paper of Hirai et al^[12] from 2010 as this data was updated in 2014. Moreover, Yamamoto's paper from 2004 included overlapping data with the Sunada paper from 2005^[13,14]. As the Yamamoto paper had a longer inclusion period with more patients we excluded the paper from Sunada et $al^{[14]}$. Pinho et $al^{[15]}$ published a multicenter survey on the use of device-assisted enteroscopy in Portugal, which mentioned 6 cases of DBE-assisted dilatation. However, as these data are soley based on a survey and data with regard to efficacy and follow-up is lacking we decided to exclude this paper. In total, 13 original articles were included^[2,11,13,16-25].

We performed a descriptive analysis studying patient demographics, stricture and disease characteristics, dilatation techniques, long-term and shortterm complication and success rates. Short-term success was defined as improvement of symptoms after the dilatation. The endoscopic dilatation was only considered successful when the patient was free of surgery at the end of the follow-up period. Major complications such as bleeding, perforation, pancreatitis or any event leading to hospitalization were considered in the safety assessment. Long-term success was defined as the number of patients who did not need surgery during the follow-up period. Redilatation was reported separately. In the studies that also included diagnostic enteroscopies or other doubleballoon assisted endoscopic interventions, only the data with regard to the dilatation cohort were included.

RESULTS

Study characteristics

General characteristics: In total 13 studies met the inclusion criteria mentioned above. The baseline study characteristics are listed in Table 1. All studies had a retrospective study design and the number of patients enrolled ranged from 8-156 patients. Fifty percent of the 626 patients (n = 316) that were included were



Author	Year of publication	# patients	# patients undergoing dilatations	Total # strictures dilated	Aetiology stricture	Length stricture (cm)	FU (months)
Yamamoto et al ^[13]	2004	23	6	6	Mixed	NR	NR
Pohl et al ^[16]	2006	19	9	13	CD	$\leqslant 4$	16 (4-26)
Ohmiya et al ^[17]	2009	66	22	47	Mixed	NR	16 (2-43)
Despott et al ^[18]	2011	11	9	18	CD	< 5	20.5 (2-41)
Hayashi <i>et al</i> ^[19]	2008	18	2	2	NSAID	NR	NR
Hirai et al ^[11]	2014	65	52	52	CD	≤ 5	41.8 ± 24.9
Gill et al ^[20]	2014	32	14	15	Mixed	NR	16 (3-60)
Irani et al ^[21]	2012	13	12	17	Mixed	≤ 2	46
Nishimura et al ^[22]	2011	8	7	11	Ischemic	≤ 3	16
Fukumoto et al ^[23]	2007	156	31	50	Mixed	NR	11.9 (1-40)
Sunada et al ^[24]	2016	99	85	291	CD	< 5	41.9
Kita et al ^[25]	2006	NR (at least 45)	45	45	Mixed	NR	NR
Kroner et al ^[2]	2015	71	16	16	Mixed	NR	NR
Total		626	310	583			

CD: Crohn's disease; NSAIDS: Non-steroidal anti-inflammatory drugs; NR: Not reported.




Figure 1 Study results. This flowchart summarizes the study results with the outcomes of the patients that were dilated.

not dilated. The reasons included technical difficulty reaching the stricture due to anatomical variations such as angulation or adhesions (n = 14) or once at the stricture, it was difficult to maintain a stable wire or scope position (n = 7). Other reasons were evidence of active inflammation at the stricture site which was then managed medically (n = 28), or the stricture was

not obstructing and therefore not treated (n = 16) (Figure 1). In total, 581 dilatations were performed in the included 310 patients.

Study heterogeneity: There was a significant heterogeneity among the studies and they differed in terms of study aims, patient population and dilatation techniques. However, all studies described at least the short-term success and complication rates of the EBD. Moreover, the enrolled patients differed between the studies: seven studies included all causes of small bowel strictures, whereas in four series the study population was limited to patients with CD, one series only described NSAID-related strictures and one series was limited to ischemic strictures. The length of the stricture varied but none of the studies included strictures above 5cm in length. The inclusion and exclusion criteria of the studies are reported in Table 2.

Dilatation technique

Balloon characteristics: The details of the dilatation technique that was used are specified in Table 3. The controlled radial expansion (CRE) wire guided balloon dilator (Boston Scientific Corporation, Natick, Mass) was the most commonly used (at least 8/13 studies). Five papers did not specify the type of balloon that was used. Four studies reported a maximum dilatation diameter of 20 mm, whereas the other studies went up to 12 mm (one study), 13 mm (one study), 16.5 mm (one study) or 18 mm (two studies). In four studies the diameter was not reported. There was also some variability in the duration of each dilatation. Most studies dilated for 30-60 s, whereas in two studies the dilatation duration was up to 120 s per patient.

Fluoroscopy: Fluoroscopic guidance was used in five studies, whereas two studies performed the dilatation purely under direct vision. The other five papers did not make a remark regarding the use of fluoroscopy.

WJG | www.wjgnet.com

Baars JE et al. Double-balloon enteroscopy-assisted dilatation avoids surgery

Author	Year of publication	Inclusion criteria	Exclusion criteria
Yamamoto et al ^[13]	2004	- Retrospective review of all DBEs - Dilatation criteria NR	- NR
Pohl et al ^[16]	2006	- Known or suspected CD and proven or suspicious small bowel strictures - Dilatation criteria NR	- Strictures > 5 cm or including significant angulation or severe active inflammation with ulcerations
Ohmiya et al ^[17]	2009	- Patients with SBO	- Acute obstruction with strangulation or suspected perforation
		 The stricture was assumed to be restricted within narrow limits in the small bowel assessed by radiologic imaging A second dilation session was only performed if obstructive symptoms recurred 	- A stricture with a deep open ulcer
Despott et al ^[18]	2011	- CD patients with small bowel stricture - Dilatation criteria NR	- Strictures > 5 cm
Hayashi <i>et al</i> ^[19]	2008	 Retrospective case series of all patients who had undergone DBE In the case of a diaphragm-like stricture, all the strictures were dilated 	-NR
Hirai et al ^[11]	2014	CD patients with: - Small bowel strictures causing obstructive symptoms - Stricture length ≤ 5 cm - No associated fistula or abscess - no deep ulcer - No severe curvature of the stricture	- Stricture of the ileocolonic anastomosis - Post-dilatation observation period < 6 mo - Patients who did not meet dilatation criteria
Gill et al ^[20]	2014	 Retrospective review: All patients with suspected strictures in the small bowel undergoing DBE Dilatation criteria NR 	 Patients with severely ulcerated or inflamed strictures Patients in whom the scope could not traverse the stricture
Irani et al ^[21]	2012	- Clinical and radiological evidence (CT or small bowel follow through) of small bowel obstruction	- Malignant strictures and masses found either at video capsule endoscopy or DBE
Nishimura <i>et al</i> ^[22]	2011	 Patients with ischemic enteritis and a segment of intestine that could not be passed by the enteroscope Dilation was indicated when there were symptoms of intestinal obstruction and evidence of caliber change by CT scan 	- Deep ulcerations
Fukumoto <i>et al</i> ^[23]	2007	A stricture was defined by 1 or more of the following criteria: - DBE showed the internal diameter of the bowel lumen to be < 10 mm or the endoscope could not pass through the lesion - The patient complained of obstructive symptoms - Stricture was suggested or identified by other modalities.	-Asymptomatic patient (even when the endoscope did not pass through the stricture)
Sunada et al ^[24]	2016	- Retrospective review of all DBEs - Dilatation criteria NR	-NR
Kita et al ^[25]	2006	- Dilation Criteria NR - Retrospective review of all DBEs - Dilatation criteria NR	-NR
Kroner <i>et al</i> ^[2]	2015	- Retrospective review of consecutive patients who were found to have small bowel stricture at the time of DBE - Benign appearance of the stricture	- Malignant (appearance of) strictures

CD: Crohn's disease; NR: Not reported; SBO: Small bowel obstruction; DBE: Double balloon enteroscopy.

Sedation: In four studies all dilatations were done under conscious sedation, and in one study all dilatations were done under conscious sedation or propofol. In another five studies the method of sedation was not mentioned. Despott *et al*^[18] used general anesthesia in 9 procedures, with midazolam and pethidine in 2 procedures and anesthesist-delivered propofol sedation in 1 procedure. Irani *et al*^[21] used general anesthesia in seven patients and conscious sedation in 6 others.

Study outcomes

Follow-up: The follow-up duration was reported in 9

out of 13 studies and varied from 11.9 - 46.0 mo. In 68 patients (22%) there was no follow-up data, which was either not reported in the study or the patient was lost to follow-up. The total follow-up time was 7750.5 mo for 241 patients leading to an average follow-up time of 31.8 mo per patient.

Clinical efficacy: Among those who underwent EBD, 80% achieved long-term success without the need for surgery during follow-up (n = 192/241 patients). In total, 20% required surgery during the study-period (n = 49/241 patients), either because of a complication

Author	Year of publication	Balloon diameter (mm)	Duration of dilatation per stricture (s)	Type of balloon	Fluoroscopy	Sedation CS/ GA
Yamamoto et al ^[13]	2004	NR	NR	Boston Scientific, CRE	NR	CS
Pohl et al ^[16]	2006	Up to 20	120	Boston Scientific, CRE	Yes	NR
Ohmiya et al ^[17]	2009	8-20	60	NR	NR	NR
Despott et al ^[18]	2011	12-20	60	Boston Scientific, CRE	No	CS and GA
Hayashi et al ^[19]	2008	NR	NR	Boston Scientific, CRE	NR	NR
Hirai et al ^[12]	2014	12-18	30-120	Boston Scientific, CRE	NR	CS
Gill et al ^[20]	2014	10-16.5	NR	Boston Scientific, CRE	No	CS or propofol
Irani et al ^[21]	2012	10-18	30 or until waist effacement	NR	Yes	CS and GA
Nishimura et al ^[22]	2011	8-12	30 (and 30 s interval)	Boston Scientific, CRE	Yes	CS
Fukumoto et al ^[23]	2007	NR	NR	NR	Yes	NR
Sunada et al ^[24]	2016	8-20	30-60	Boston Scientific, CRE	Yes	CS
Kita et al ^[25]	2006	NR	NR	NR	NR	NR
Kroner et al ^[2]	2015	13	NR	NR	NR	GA

CS: Conscious sedation; GA: General anesthesia; CRE: Controlled radial expansion; NR: Not reported.

of the EBD (n = 9) or because of a relapse (n = 40).

Excluding those who needed surgery due to a complication of the EBD, 37% of patients did not need further treatment after the initial EBD. In total, 63% was retreated because of a relapse or underwent prophylactic re-dilatation. Unfortunately, one study with a high re-dilatation rate did not report the reason for re-dilatation and the relapse rate can therefore not be precisely reported^[24]. Of the 146 patients who needed retreatment, 27% underwent surgery (n = 40) and 46% successfully underwent EBD (n = 106). The study results are summarized in Figure 1 below.

Complications: The complications are listed in Table 4. The total complication rate per patient was 4.8% (15/310 patients), whereas the total complication rate per dilatation was 2.6% (15/583 dilatations). This included 5 patients with a perforation, 3 patients with acute pancreatitis, 1 patient who suffered from hemorrhage that required blood transfusions and 3 patients with hyperamylasemia. The patient with pancreatitis recovered after a short hospital stay and the patients with perforations all underwent surgery.

DISCUSSION

In this systematic review we demonstrate that doubleballoon assisted dilatation is a safe and effective treatment for small bowel strictures. Four out of five patients avoid surgery due to double-balloon assisted dilatation of their small bowel stricture in an average follow-up of 2.5 years per patient.

Small bowel strictures are associated with major comorbidity and usually require treatment. Surgery has been the main treatment option in the past. Moreover, the management of small bowel strictures, especially in CD, is often a clinical challenge because of the high recurrence rate and many patients need surgery more than once. Although surgery often results in symptomatic resolution, repeat surgery is often needed which can result in short bowel syndrome and malnutrition^[26,27]. Our study showed that DBEassisted balloon dilatation is effective in avoiding surgery as only 17% of patients required surgery due to a relapse.

In our study cohort, 47% of patients underwent redilatation during the follow-up period. It is known that strictures often recur, especially in $CD^{[26,27]}$. Even after stricturoplasty, repeat surgery may be as high as 25% over a follow-up of 2.5 years^[28]. In our study, surgery was avoided in 80% of cases.

Hirai et al^[11] reported an unusually high repeat DBE rate (85.6%). This can be explained by the fact that their protocol included a routine re-examination and prophylactic re-intervention if a stricture was seen. In total 45 out of 52 successful EBD cases were reexamined to confirm the condition of the strictures after initial EBD. Of these 45 patients, 26 patients needed a secondary EBD of which 7 patients were asymptomatic. Sunada et al^[24]. also reported a very high repeat DBE rate, but again they also performed repeat EBD in asymptomatic patients. They did not report how many patients actually needed retreatment because of a relapse. In the other studies, patients only underwent a repeat enteroscopy if they were symptomatic. There is currently no role for scheduled re-dilatation if patients are asymptomatic as there is no literature available to support scheduled redilatation. However, if patients are symptomatic redilatation would need to be considered.

In our study cohort a complication rate of 4.8% per patient and 2.6% per dilatation was demonstrated. This is comparable with previous studies. In 2007, Mensink *et a*^[10] reported a complication rate of 4.3% in therapeutic double-balloon enteroscopic procedures. In the included study of Ohmiya *et a*^[17] data of 668 DBE examinations were reported, of which there were 3 cases of complicating perforation that required surgery (0.45%). However, no complicating perforation occurred in patients during or after enteroscopic balloon dilation and these complications were therefore not included in our study cohort. In our cohort of 310

Baishideng®

WJG | www.wjgnet.com

AutorComplicationType of complicationType of complicationComplicationRest and rest an	Table 4 Overv	iew of endoscop	Table 4 Overview of endoscopic balloon dilation-associated complications per study	ated complications per	study				
Yamamoto et al (b)NONA0%0%0%0%Print a d (b)NONA0%0%9/9 (00)6/9 (00)6/9 (00)Despot a d (b)NONONA0%0%9/9 (00)18/3 (00)6/9 (00)Despot a d (b)NONONA0%0%9/9 (00)8/9 (00)8/9 (00)Despot a d (b)NONA0%0%2/2 (00)8/9 (00)8/9 (00)Hara a d (b)NDNDNA0%0%0%8/9 (00)8/9 (00)Hara a d (b)NDNDNDNDNDNDNDCall et al (b)NDNDND0%0%0%0%Hara a d (b)NDNDNDNDNDND1/1/14 (79)1/1/14Status at a d (b)NDNDNDNDNDND1/1/14 (79)1/1/14Status at a d (b)NDNDNDNDNDNDND1/1/14 (79)1/1/14Status at a d (b)NDNDNDNDNDNDND1/1/14 (79)1/1/14Status at a d (b)NDNDNDNDNDNDNDNDStatus at a d (b)NDNDNDNDNDNDNDStatus at a d (b)NDNDNDNDNDNDStatus at a d (b)NDNDNDNDNDND </th <th>Author</th> <th>Complications</th> <th>Type of complication</th> <th>Complication rate per patient</th> <th>Complication rate per dilatation</th> <th>Short-term success² (%)</th> <th>Long-term success avoiding surgery² (%)</th> <th>Surgery² (%)</th> <th>Re-Dilatations^{2,3} (%)</th>	Author	Complications	Type of complication	Complication rate per patient	Complication rate per dilatation	Short-term success ² (%)	Long-term success avoiding surgery ² (%)	Surgery ² (%)	Re-Dilatations ^{2,3} (%)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yamamoto et al ^[13] Pobl et al ^[16]	ON	NA NA	%0 0	%0 %0	6/6 (100) 9 /9 /100)	NR 679(67)	NR 3/9(33)	NR 279(77)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Obmitte $at al^{[17]}$	NO ¹	NA	%0 0	%0 0%	(1001) 6/6 20/22/1000	(70) < 70 18 / 77 (87)	4 / 77 (18)	(71) <i>CC</i> /2
Hayesht et al ^[1] NO NA 0% 2/2 (100) NA Hayesht et al ^[2] YBS Hemorating (n = 1) 12% 2/2 (203) 44/22 Hira et al ^[2] YBS Hemoration (n = 1) Perforation (n = 1) 11/14 Removation (n = 1) Perforation (n = 1) Perforation (n = 2) 13% 13% 11/14 Immit et al ^[2] YBS Perforation (n = 2) 13% 13% 11/14 Nishimus et al ^[2] NO NA 0% 6% 6/7 (86) 4/7 (86) Stand et al ^[2] NO NA 0% 0% 6/7 (86) 4/7 (86) 4/7 (86) Stand et al ^[2] NO NA 0% 0% 6/7 (86) 4/7 (86) 4/7 (86) Stand et al ^[2] NO NA 0% 0% 6/7 (86) 4/7 (86) 4/7 (86) Stand et al ^[2] NO NA 0% 0% 6/7 (86) 4/7 (8) 2/7 (8) Stand et al ^[2] NO NO NA 0%	Despott et al ^[18]	YES	Perforation $(n = 1)$	11%	5.6%	8/9 (89)	8/9 (89)	$\frac{1}{1}$ (11)	2/9 (22)
Hira et al in the structure parcenting (n = 1)12%12%48/52 (92.3)44/52Active parcenting (n = 1)Active parcenting (n = 1)12%48/52 (92.3)44/52Active parcenting (n = 1)Active parcenting (n = 1)13%11/14 (79)11/14Call et al ⁽²⁾¹ YESPerforation (n = 2)13%13%11/14 (79)11/14Nishtura et al ⁽²⁾¹ YESPerforation (n = 2)13%0%0/7 (80)4/7 (70)Nishtura et al ⁽²⁾¹ NONA0%0%0%0/7 (80)10/12 (80)0/1 (80)Sumade et al ⁽²⁾¹ YESPerforations (n = 4)6%0%0%0%0/7 (80)NitSumade et al ⁽²⁾¹ NONA0%0%0%0%0%0/7 (80)NitTotalNONA0%0%0%0%0%0/7 (80)NitTotalNONA0%0%0%0%0/7 (80)NitTotalNONA0%0%0%0%0/7 (80)NitTotalNONA0%0%0%0%0/7 (80)NitTotalNONA0%0%0%0%0/7 (80)NitTotalNONA0%0%0%0%0/7 (80)NitTotalActorNONA0%0%0%0%0/7 (80)TotalActorNONA0%0%0%0%0% <td< td=""><td>Hayashi <i>et al</i>^[19]</td><td>ON</td><td>NA</td><td>%0</td><td>%0</td><td>2/2 (100)</td><td>NR</td><td>NR</td><td>NR</td></td<>	Hayashi <i>et al</i> ^[19]	ON	NA	%0	%0	2/2 (100)	NR	NR	NR
Acute parcreatitis ($t = 1$) Perforation ($t = 1$) Hyperanylasemia ($t = 3$) Kitha $t al^{23}$ No NA Kroner et al^{23} No NA NA NA NA NA NA NA NA NA NA	Hirai et al ^[12]	YES	Haemorrhage $(n = 1)$	12%	12%	48/52 (92.3)	44/52 (85)	8/52 (15)	26/52 (50)
Call et a_{1}^{PM} Typerany ascand ($n = 3$)13%13%11/14 (79)11/14 (79)11/14 (79)Irani et a_{1}^{PM} YESPerforation ($n = 2$)8%6%0%6/7 (8%)4/7 (9)Nishimura et a_{1}^{PM} NONA0%0%6/7 (8%)4/7 (9)10/12 (83)10/12 (83)Submoto et a_{1}^{PM} YESPerforations ($n = 4$)0%0%6/7 (8%)4/7 (8)4/7 (8)Submoto et a_{1}^{PM} YESPerforations ($n = 4$)0%0%6/7 (8%)4/7 (8)Submoto et a_{1}^{PM} NONA0%0%6/7 (8%)4/7 (8)Submoto et a_{1}^{PM} NONA0%6%2/32/345 (100)NIRKroner et a_{1}^{PM} NONA0%6%3/345 (100)NIRKroner et a_{1}^{PM} NONA0%6%5/329 (94.3)192/34TotalHaemorthage ($n = 1$)14.8%3%263/229 (94.3)192/34Predoration ($n = 9$)Hyperamylasemia ($n = 9$)Hyperamylasemia ($n = 3$)3%263/229 (94.3)192/34Protomer et a_{1}^{PM} NONA0%0%15/16 (100)NIRProtomer et a_{1}^{PM} NONA0%10/16 (100)NIRProtomer et a_{1}^{PM} NONA0%10/16 (100)NIRProtomer et a_{1}^{PM} NONA0%10/16 (100)NIRProtomer et a_{1}^{PM} NONA0%10/16 (1			Acute pancreatitis $(n = 1)$ Perforation $(n = 1)$						
Trani <i>et al</i> ^[21] YES retraction (<i>n</i> = 1) 8% 6% 10/12 (8) 10/12 (8) Nishimura <i>et al</i> ^[22] NO NA NA 0% 0% 6% 10/12 (8) 4/7 (8) Fukumoto <i>et al</i> ^[23] NO NA 0% 0% 0% 6/7 (8) 4/7 (8) Sunada <i>et al</i> ^[23] NO NA 0% 0% 0% 6/7 (8) 4/7 (9) Kita <i>et al</i> ^[23] NO NA 0% 0% 0% 6/7 (8) 16/16 (100) NF Kromer <i>et al</i> ^[23] NO NA 200 0% 0% 16/16 (100) NF Romer <i>et al</i> ^[23] NO NA 200 0% 0% 15/16 (100) NF Romer <i>et al</i> ^[23] NO NA 100% 0% 0% 15/16 (100) NF Note <i>et al</i> ^[23] NO NA 100% 0% 0% 15/16 (100) NF Romer <i>et al</i> ^[23] NO NA 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%	C: 11 at at [30]	VEC	11y perantyiasenna (n - 3) Douforotion (n - 3)	12%	12.0%	102/ 11/ 11	11/170/	(10/71/2	
Trant et al ^[24] ND Perforations (n = 1) 6.8 0.0 NA 0.0 NA 0.8 0.0 0.8 0.7 (86) 1.7 (76) 1.8 (7.8 0.0 / 1.2 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 (7.8 0.0 / 1.2 (7.8 (7.8 (7.8 (7.8 (7.8 (7.8 (7.8 (7.8		1150	1 EITOI AUDIT (n - 2)	0/CT	0/ CT	(67) #1 /11	(77) 14 (77)	(17)#1/0	(7) 11 /1
Nishimura et $a_{1}^{(n)}$ NO NO NA 0% NA 0% NA 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%	Irani et al ^{izij}	YES	Perforation $(n = 1)$	8%	9%9	10/12 (83)	10/12(83)	2/12(15)	2/12(15)
Fukumoto <i>et al^[24]</i> NO NA 0% NR 27/31 Sunada <i>et al^[24]</i> YIS Perforations (<i>n</i> = 4) 6% 2% 80/85 (94) 64/85 Sunada <i>et al^[24]</i> NO NA 0% 45/45 (100) Ni Kina <i>et al^[24]</i> NO NA 0% 64/85 64/85 64/85 Konner <i>et al^[24]</i> NO NA 0% 65/45 (100) Ni Konner <i>et al^[24]</i> NO NA 0% 64/85 64	Nishimura <i>et al</i> ^[22]	NO	NA	%0	%0	6/7 (86)	4/7 (60)	3/7 (43)	1/7(14)
Sunada et $a^{[24]}$ YESPerforations $(n = 4)$ $6.\%$ 2% $80/85 (94)$ $64/85$ Kita et $a^{[24]}$ NONA 0% 6% $45/45 (100)$ NFKita et $a^{[24]}$ NONA 0% 6% $45/45 (100)$ NFKromer et $a^{[14]}$ NONA 0% 6% $45/45 (100)$ NFTotalHaemorrhage $(n = 1)$ 1.8% 3% $263/279 (94.3)$ $192/34$ TotalHaemorrhage $(n = 1)$ 4.8% 3% $263/279 (94.3)$ $192/34$ Perforation $(n = 9)$ Hyperamylasemia $(n = 3)$ $192/34$ $192/34$ Hyperamylasemia $(n = 3)$ Hyperamylasemia $(n = 3)$ $192/34$ $192/34$ 'No complications mentioned in dilatation-cohort, 2^{i} patient lost to follow-up; 'Either because of a relapse or as prophylaxis; 'No data reported on indication for reperitor in patients. 100% 100% 'No complications mentioned in dilatation-cohort, 2^{i} patient lost to follow-up; 'Either because of a relapse or as prophylaxis; 'No data reported on indication for reperitoric for patients. 100% 100% 'No complications mentioned in dilatation-cohort, 2^{i} patient lost to follow-up; 'Either because of a relapse or as prophylaxis; 'No data reported on indication for reperitoric for the autice (2.9\%) 100% 100% 'No complications mentioned in previous studies 100% 100% 100% 100% 'No complication when risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly sh	Fukumoto <i>et al</i> ^[23]	NO	NA	0%	0%	NR	27/31 (87)	4/31(13)	5/31 (16)
Kita <i>et al</i> ^[2] NONA 0% 0% $45/45$ (100)NBKroner <i>et al</i> ^[2] NONA 0% 0% $16/16$ (100)NBTotalHaemorrhage (<i>n</i> = 1) 4.8% 3% $263/279$ (94.3) $192/24$ TotalAcute parcreatitis (<i>n</i> = 1) 4.8% 3% $263/279$ (94.3) $192/24$ Perforation (<i>n</i> = 9)Hyperamylasemia (<i>n</i> = 3)Bleeding (<i>n</i> = 1) 1.8% $2.63/279$ (94.3) $192/24$ No complications mentioned in dilatation-cohort, ² 1 patient lost to follow-up; ¹ Either because of a relapse or as prophylaxis, ¹ No data reported on indication for reperNo complications mentioned in dilatation-cohort, ² 1 patient lost to follow-up; ¹ Either because of a relapse or as prophylaxis, ¹ No data reported on indication for reperNo complications mentioned in dilatation-cohort, ² 1 patient lost to follow-up; ¹ Either because of a relapse or as prophylaxis, ¹ No data reported on indication for reperNo complications mentioned in patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intestRhown risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.	Sunada <i>et al</i> ^[24]	YES	Perforations $(n = 4)$	9%	2%	80/85 (94)	64/85 (75)	21/85 (25)	64/85 (75) ⁴
Kita <i>et a</i> ^[23] NO NA 0% A5 (100) NB Kito <i>et a</i> ^[23] NO NA 0% 0% 45/45 (100) NB Kroner <i>et a</i> ^[23] NO NA Total Total Haemorrhage (<i>n</i> = 1) 4.8% 0% 0% 16/16 (100) NB Perforation (<i>n</i> = 9) Hyperamylasenia (<i>n</i> = 1) 7.24 (100) Performing (<i>n</i> = 1) 7.263 (100) Performing (<i>n</i> = 1) 7.24 (100) Performing (<i>n</i> = 1) 7.			Bleeding $(n = 1)$						
Kroner et $a1^{[3]}$ NONA0%16/16 (100)NRTotalHaemorrhage ($n = 1$)4.8%3%263/279 (94.3)192/241TotalAcute parcreatitis ($n = 1$) $Perforation (n = 9)Hyperarylasemia (n = 3)192/241Perforation (n = 9)Hyperarylasemia (n = 3)Bleeding (n = 1)4.8\%3\%263/279 (94.3)192/241'No complications mentioned in dilatation-cohort, 21 patient lost to follow-up' Trither because of a relapse or as prophylaxis, 4No data reported on indication for reper'No complications mentioned in dilatation-cohort, 21 patient lost to follow-up' Trither because of a relapse or as prophylaxis, 4No data reported on indication for reper'No complications mentioned in dilatation-cohort, 21 patient lost to follow-up' Trither because of a relapse or as prophylaxis, 4No data reported on indication for reper'No complications mentioned in dilatation cohort, 21 patient lost to follow-up' Trither because of a relapse or as prophylaxis, 4No data reported on indication for reper'No complications mentioned in previoutes studies[26,27,29,30]'No more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morecdilatation when there was active ulceration.$	Kita $et al^{[25]}$	NO	NA	%0	0%	45/45 (100)	NR	NR	NR
Total Total Haemorrhage $(n = 1)$ 4.8% 3% 263/279 (94.3) 192/24: Acute pancreatitis $(n = 1)$ Perforation $(n = 9)$ Hyperamylasemia $(n = 3)$ Bleeding $(n = 1)$ No complications mentioned in dilatation-cohort; ² 1 patient lost to follow-up; ³ Either because of a relapse or as prophylaxis, ⁴ No data reported on indication for reper patients, nine patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intest reported in previous studies ^[26,27,29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.	Kroner et al ^[2]	NO	NA	0%	0%	16/16 (100)	NR	NR	NR
Acute pancreatitis $(n = 1)$ Perforation $(n = 9)$ Hyperamylasemia $(n = 3)$ Bleeding $(n = 1)$ (n = 3) Bleeding $(n = 1)$ (n = 3) Bleeding $(n = 1)$ (n = 1) (n = 1) (n = 2) (n = 1) (n = 1) (Total		Haemorrhage $(n = 1)$	4.8%	3%	263/279 (94.3)	192/241 (80)	49/241 (20)	106/241(44)
¹ No complications mentioned in dilatation-cohort, ² 1 patient lost to follow-up, ³ Either because of a relapse or as prophylaxis, ⁴ No data reported on indication for reper patients, nine patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intest reported in previous studies ^[26,27/29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.			Acute pancreatitis $(n = 1)$ Perforation $(n = 9)$						
¹ No complications mentioned in dilatation-cohort, ² 1 patient lost to follow-up, ³ Either because of a relapse or as prophylaxis, ⁴ No data reported on indication for reper patients, nine patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intest reported in previous studies ^[26,27,29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.			Hyperamylasemia $(n = 3)$						
¹ No complications mentioned in dilatation-cohort; ² 1 patient lost to follow-up; ³ Either because of a relapse or as prophylaxis, ⁴ No data reported on indication for reper patients, nine patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intest reported in previous studies ^[26,27,29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.			Bleeding $(n = 1)$						
¹ No complications mentioned in dilatation-cohort, ² 1 patient lost to follow-up; ³ Either because of a relapse or as prophylaxis, ⁴ No data reported on indication for repeatents, nine patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intest reported in previous studies ^[26,277,29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.			2						
patients, nine patients (2.9%) needed surgery directly after the dilatation due to a perforation. Our reported rate of intest reported in previous studies ^[26,27,29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.	¹ No complications m	entioned in dilatati	ion-cohort; ² 1 patient lost to f	ollow-up; ³ Either because o	f a relapse or as prophylax	is; ⁴ No data reported on indic	cation for repeat dilatation an	d relapse rate. NA: Not	applicable; NR: Not reported.
patients, mile patients (2:3%) inceded surgery unectory after the dilatation due to a perioration. Our reported rate of intest reported in previous studies ^[26,27,29,30] . Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Morec dilatation when there was active ulceration.		00/ C/ 01/00/		····································			مصقحا ممتلمدها فمرطوب	odt cidtin ci cotto	/02 C 04 /00 gC 00000
Known risk factors for perforation include adhered or angulated strictures, active inflammation and dilating to more that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Moreo dilatation when there was active ulceration.	reported in prev	overus) کا افالغا vious studies ^{[2}	y needed surgery une 26,27,29,30]	ברוו) מורבו חוב חוומרמו	nul ane ma helloio	arioni. Oui Tepoliteu ia	ורב הו ווורבארוושו הבו וחו	מחסוו וא אותוווו חופ	
that the surgery-free interval in patients with a fistula was significantly shorter than in patients without a fistula. Moreo dilatation when there was active ulceration.	Known risk	factors for pe	rforation include adh	ered or angulated s	trictures, active infl	ammation and dilatir	ng to more than 15 r	nm ^[18,20] . Sunada d	et a/ ^[24] demonstrated
aliatation when there was active ulceration.	that the surger	y-free interva	ll in patients with a fi	stula was significant	:ly shorter than in p	atients without a fist	ula. Moreover, most	of the included st	udies did not perform
the second second second second level of the second s		I UNELE WAS AC	cuve ulceration.						

only. There is a large multicenter survey from Portugal on the use of device-assisted enteroscopy, which mentioned 6 cases of DBE-assisted dilatation with just one and spiral enteroscopy is very limited with only small numbers and limited follow-up. We therefore decided to focus our systematic review on DBE-assisted dilatation In this study we assess the role of DBE-assisted dilatation of small bowel strictures. The data on other modalities of enteroscopy including single balloon enteroscopy reported complication. This confirms the safety we also show in our study $^{[15]}$

Endoscopic and surgical management of small bowel strictures are not mutually exclusive options. On the contrary, these two modalities complement each other as even patients who have undergone surgical resections in the past may still be considered for endoscopic therapy. In one of the studies in our systematic review, 10 of the 11 patients had undergone previous surgery and yet the procedure was successful in 9 of them^[18].

The current study is limited by its retrospective design. Due to heterogeneity of the study designs and lack of randomized controlled trials it was not possible to perform a meta-analysis. However, this large systematic review includes a large patient group with a long average follow-up time of over 2.5 years per patient.






Figure 2 Suggested approach to small bowel. This algorithm proposes a standardized approach to small bowel strictures, taking into account the known risk factors previously demonstrated in literature.

Concomitant medical treatment was not evaluated, although we know this is important for preventing strictures and can influence the relapse-rate. Moreover, as the numbers are relatively small we could not analyze the outcomes stratified by disease. Finally, the published studies did not focus on multiple small bowel strictures. Therefore, based on this literature review we cannot analyze the outcomes of treatment of multiple small bowel strictures, nor can we comment on the optimal strategy to treat multiple small bowel strictures.

Recently, a clinical practice guideline to enteroscopy was published in Japan^[31]. In this guideline the indications for enteroscopy-assisted balloon dilatation are discussed which include symptomatic strictures that are < 5 cm long and are not associated with active inflammation or fistula/abscesses. Although the indications to EBD are described in this guideline, the general, step-wise approach for the management of small bowel strictures is currently not available. A standardized approach is beneficial as it may reduce complication rates and therewith even further increase the beneficial effect of DBE-assisted balloon dilatation. Taking into account the known risk factors previously demonstrated in literature and discussed in the Japanese guideline we propose the algorithm demonstrated in Figure 2 as a standardized approach to small bowel strictures.

In this algorithm we propose that at first high risk features such as active inflammation/ulceration, large



Figure 3 Double-balloon enteroscopy -assisted balloon dilatation. An example of a successful double-balloon enteroscopy (DBE)-assisted balloon dilatation is presented. A: shows the endoscopic image of a benign small bowel stricture in one of our patients. This patient was known with Crohn's disease and had had prior small bowel surgery. She presented with obstructive symptoms and a fibrotic stricture at the side of the anastomosis. B: The stricture was dilated with DBE-assisted balloon dilation; C: Shows the anastomotic stricture after successful dilatation. This picture reveals the surgical staples at the anastomosis and there were no signs of active Crohn's disease.

stricture and sharp angulation should be considered. In case there are no high risk features endoscopic therapy can be performed safely. An illustration of endoscopic balloon dilatation is shown in Figure 3A-C. If the symptoms have resolved after endoscopic therapy no further dilatation is required and the patient should be observed. However, if symptoms do recur, endoscopic re-dilatation or finally surgery has to be considered.

In conclusion, DBE is a safe and effective tool in the management of small bowel strictures and avoids unnecessary surgery in the majority of patients. DBEassisted EBD should therefore be considered in all



patients with small bowel strictures.

ARTICLE HIGHLIGHTS

Research background

At present there is a wealth of literature on the value of double-balloon enteroscopy (DBE) in the management of obscure gastrointestinal bleeding. However, there is only few data regarding its role in small bowel strictures. The management of small bowel strictures is complicated and these patients often face surgery, which has a huge impact on their quality of life.

Research motivation

In this study we aimed to evaluate the therapeutic role of DBE in small bowel strictures. In addition, we aimed to propose a standard approach to the management of small bowel strictures.

Research objectives

The main objective of this manuscript was to assess the efficacy and safety of DBE-assisted balloon dilatation of small bowel strictures. This is important as many of these patients often face surgery. The authors aimed to assess the role of DBE-assisted dilatation as an alternative for surgery.

Research methods

This study is a systematic review of published papers on DBE-assisted dilatation of small bowel strictures. Only studies limited to small bowel strictures were included and those with ileo-colonic strictures were excluded.

Research results

In total 13 studies were included, in which 310 patients were dilated. The average follow-up time was 31.8 mo per patient. The complication rate was 4.8% per patient and 2.6% per dilatation. Surgery was avoided in 80% of patients. After the first dilatation, 46% were treated with re-dilatation and only 17% required surgery.

Research conclusions

In this systematic review we demonstrate that double-balloon assisted dilatation is a safe and effective treatment for small bowel strictures. Four out of five patients avoid surgery due to double-balloon assisted dilatation of their small bowel stricture in an average follow-up of 2.5 years per patient. Moreover, we propose a flow-chart representing a standard approach to small bowel strictures.

Research perspectives

This research shows that double-balloon assisted balloon-dilatation is a safe and effective treatment for small bowel strictures and should be considered as a first treatment options. Future research is needed to explore the options of balloon-assisted enteroscopy in other device-assisted enteroscopy modalities.

REFERENCES

- Jackson BT. Bowel damage from radiation. Proc R Soc Med 1976; 69: 683-686 [PMID: 981272]
- 2 Kroner PT, Brahmbhatt BS, Bartel MJ, Stark ME, Lukens FJ. Yield of double-balloon enteroscopy in the diagnosis and treatment of small bowel strictures. *Dig Liver Dis* 2016; 48: 446-448 [PMID: 26725164 DOI: 10.1016/j.dld.2015.11.019]
- 3 **Gardiner KR**, Dasari BV. Operative management of small bowel Crohn's disease. *Surg Clin North Am* 2007; **87**: 587-610 [PMID: 17560414 DOI: 10.1016/j.suc.2007.03.011]
- 4 Lee EC, Papaioannou N. Minimal surgery for chronic obstruction in patients with extensive or universal Crohn's disease. *Ann R Coll Surg Engl* 1982; 64: 229-233 [PMID: 7092090]
- 5 Parker MC, Wilson MS, Menzies D, Sunderland G, Clark DN, Knight AD, Crowe AM; Surgical and Clinical Adhesions Research (SCAR) Group. The SCAR-3 study: 5-year adhesion-related readmission risk following lower abdominal surgical procedures.

Colorectal Dis 2005; **7**: 551-558 [PMID: 16232234 DOI: 10.1111/ j.1463-1318.2005.00857.x]

- 6 Bellolio F, Cohen Z, MacRae HM, O'Connor BI, Victor JC, Huang H, McLeod RS. Strictureplasty in selected Crohn's disease patients results in acceptable long-term outcome. *Dis Colon Rectum* 2012; 55: 864-869 [PMID: 22810471 DOI: 10.1097/ DCR.0b013e318258f5cb]
- 7 Saunders BP, Brown GJ, Lemann M, Rutgeerts P. Balloon dilation of ileocolonic strictures in Crohn's disease. *Endoscopy* 2004; 36: 1001-1007 [PMID: 15520920 DOI: 10.1055/s-2004-825962]
- 8 Yamamoto H, Sekine Y, Sato Y, Higashizawa T, Miyata T, Iino S, Ido K, Sugano K. Total enteroscopy with a nonsurgical steerable double-balloon method. *Gastrointest Endosc* 2001; **53**: 216-220 [PMID: 11174299]
- 9 **Karstensen JG**, Hendel J, Vilmann P. Endoscopic balloon dilatation for Crohn's strictures of the gastrointestinal tract is feasible. *Dan Med J* 2012; **59**: A4471 [PMID: 22759846]
- 10 Mensink PB, Haringsma J, Kucharzik T, Cellier C, Pérez-Cuadrado E, Mönkemüller K, Gasbarrini A, Kaffes AJ, Nakamura K, Yen HH, Yamamoto H. Complications of double balloon enteroscopy: a multicenter survey. *Endoscopy* 2007; **39**: 613-615 [PMID: 17516287 DOI: 10.1055/s-2007-966444]
- 11 Hirai F, Beppu T, Takatsu N, Yano Y, Ninomiya K, Ono Y, Hisabe T, Matsui T. Long-term outcome of endoscopic balloon dilation for small bowel strictures in patients with Crohn's disease. *Dig Endosc* 2014; 26: 545-551 [PMID: 24528293 DOI: 10.1111/den.12236]
- 12 Hirai F, Beppu T, Sou S, Seki T, Yao K, Matsui T. Endoscopic balloon dilatation using double-balloon endoscopy is a useful and safe treatment for small intestinal strictures in Crohn's disease. *Dig Endosc* 2010; 22: 200-204 [PMID: 20642609 DOI: 10.1111/ j.1443-1661.2010.00984.x]
- 13 Yamamoto H, Kita H, Sunada K, Hayashi Y, Sato H, Yano T, Iwamoto M, Sekine Y, Miyata T, Kuno A, Ajibe H, Ido K, Sugano K. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. *Clin Gastroenterol Hepatol* 2004; 2: 1010-1016 [PMID: 15551254]
- 14 Sunada K, Yamamoto H, Kita H, Yano T, Sato H, Hayashi Y, Miyata T, Sekine Y, Kuno A, Iwamoto M, Ohnishi H, Ido K, Sugano K. Clinical outcomes of enteroscopy using the doubleballoon method for strictures of the small intestine. *World J Gastroenterol* 2005; 11: 1087-1089 [PMID: 15742422 DOI: 10.3748/wjg.v11.i7.1087]
- 15 Pinho R, Mascarenhas-Saraiva M, Mão-de-Ferro S, Ferreira S, Almeida N, Figueiredo P, Rodrigues A, Cardoso H, Marques M, Rosa B, Cotter J, Vilas-Boas G, Cardoso C, Salgado M, Marcos-Pinto R. Multicenter survey on the use of device-assisted enteroscopy in Portugal. *United European Gastroenterol J* 2016; 4: 264-274 [PMID: 27087956 DOI: 10.1177/2050640615604775]
- 16 Pohl J, May A, Nachbar L, Ell C. Diagnostic and therapeutic yield of push-and-pull enteroscopy for symptomatic small bowel Crohn' s disease strictures. *Eur J Gastroenterol Hepatol* 2007; 19: 529-534 [PMID: 17556897 DOI: 10.1097/MEG.0b013e328012b0d0]
- 17 Ohmiya N, Arakawa D, Nakamura M, Honda W, Shirai O, Taguchi A, Itoh A, Hirooka Y, Niwa Y, Maeda O, Ando T, Goto H. Small-bowel obstruction: diagnostic comparison between doubleballoon endoscopy and fluoroscopic enteroclysis, and the outcome of enteroscopic treatment. *Gastrointest Endosc* 2009; **69**: 84-93 [PMID: 19111689 DOI: 10.1016/j.gie.2008.04.067]
- 18 Despott EJ, Gupta A, Burling D, Tripoli E, Konieczko K, Hart A, Fraser C. Effective dilation of small-bowel strictures by doubleballoon enteroscopy in patients with symptomatic Crohn's disease (with video). *Gastrointest Endosc* 2009; **70**: 1030-1036 [PMID: 19640518 DOI: 10.1016/j.gie.2009.05.005]
- 19 Hayashi Y, Yamamoto H, Taguchi H, Sunada K, Miyata T, Yano T, Arashiro M, Sugano K. Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease. J Gastroenterol 2009; 44 Suppl 19: 57-63 [PMID: 19148795 DOI: 10.1007/s00535-008-2277-3]
- 20 Gill RS, Kaffes AJ. Small bowel stricture characterization and

outcomes of dilatation by double-balloon enteroscopy: a singlecentre experience. *Therap Adv Gastroenterol* 2014; **7**: 108-114 [PMID: 24790641 DOI: 10.1177/1756283X13513995]

- 21 Irani S, Balmadrid B, Seven G, Ross A, Gan SI, Gluck M, Kozarek R. Balloon dilation of benign small bowel strictures using double balloon enteroscopy: 5-year review from a single tertiary referral center. *Gastrointestinal Intervention* 2012; 1: 74-78 [DOI: 10.1016/j.gii.2012.08.007]
- 22 Nishimura N, Yamamoto H, Yano T, Hayashi Y, Sato H, Miura Y, Shinhata H, Sunada K, Sugano K. Balloon dilation when using double-balloon enteroscopy for small-bowel strictures associated with ischemic enteritis. *Gastrointest Endosc* 2011; 74: 1157-1161 [PMID: 21924719 DOI: 10.1016/j.gie.2011.07.024]
- 23 Fukumoto A, Tanaka S, Yamamoto H, Yao T, Matsui T, Iida M, Goto H, Sakamoto C, Chiba T, Sugano K. Diagnosis and treatment of small-bowel stricture by double balloon endoscopy. *Gastrointest Endosc* 2007; 66: S108-S112 [PMID: 17709019 DOI: 10.1016/ j.gie.2007.02.027]
- 24 Sunada K, Shinozaki S, Nagayama M, Yano T, Takezawa T, Ino Y, Sakamoto H, Miura Y, Hayashi Y, Sato H, Lefor AK, Yamamoto H. Long-term Outcomes in Patients with Small Intestinal Strictures Secondary to Crohn's Disease After Double-balloon Endoscopy-assisted Balloon Dilation. *Inflamm Bowel Dis* 2016; 22: 380-386 [PMID: 26535767 DOI: 10.1097/MIB.000000000000627]
- 25 **Kita H**, Yamamoto H, Yano T, Miyata T, Iwamoto M, Sunada K, Arashiro M, Hayashi Y, Ido K, Sugano K. Double balloon

endoscopy in two hundred fifty cases for the diagnosis and treatment of small intestinal disorders. *Inflammopharmacology* 2007; **15**: 74-77 [PMID: 17450446 DOI: 10.1007/s10787-006-1568-7]

- 26 Mueller T, Rieder B, Bechtner G, Pfeiffer A. The response of Crohn' s strictures to endoscopic balloon dilation. *Aliment Pharmacol Ther* 2010; **31**: 634-639 [PMID: 20047581 DOI: 10.1111/ j.1365-2036.2009.04225.x]
- 27 Thienpont C, D'Hoore A, Vermeire S, Demedts I, Bisschops R, Coremans G, Rutgeerts P, Van Assche G. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. *Gut* 2010; 59: 320-324 [PMID: 19840991 DOI: 10.1136/gut.2009.180182]
- 28 Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease: meta-analysis. *Dis Colon Rectum* 2000; 43: 911-919 [PMID: 10910235]
- 29 Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: Endoscopic dilatation in Crohn's disease. *Aliment Pharmacol Ther* 2007; 26: 1457-1464 [PMID: 17903236 DOI: 10.1111/j.1365-2036.2007.03532.x]
- 30 Scimeca D, Mocciaro F, Cottone M, Montalbano LM, D'Amico G, Olivo M, Orlando R, Orlando A. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. *Dig Liver Dis* 2011; 43: 121-125 [PMID: 20561831 DOI: 10.1016/j.dld.2010.05.001]
- 31 Yamamoto H, Ogata H, T M, Ohmiya N. Clinical practice guideline for enteroscopy. *Dig Endosc* 2017 [DOI: 10.1111/den.12883]

P- Reviewer: Huang LY, Ogata H, Pinho R S- Editor: Qi Y L- Editor: A E- Editor: Huang Y







Published by Baishideng Publishing Group Inc

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com





© 2017 Baishideng Publishing Group Inc. All rights reserved.